Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 2:13:826811.
doi: 10.3389/fphys.2022.826811. eCollection 2022.

The Role of Peroxisome Proliferator-Activated Receptor Gamma and Atherosclerosis: Post-translational Modification and Selective Modulators

Liqin Yin  1 , Lihui Wang  2 , Zunhan Shi  1 , Xiaohui Ji  1 , Longhua Liu  1
Affiliations
Review

The Role of Peroxisome Proliferator-Activated Receptor Gamma and Atherosclerosis: Post-translational Modification and Selective Modulators

Liqin Yin et al. Front Physiol. .

Abstract

Atherosclerosis is the hallmark of cardiovascular disease (CVD) which is a leading cause of death in type 2 diabetes patients, and glycemic control is not beneficial in reducing the potential risk of CVD. Clinically, it was shown that Thiazolidinediones (TZDs), a class of peroxisome proliferator-activated receptor gamma (PPARγ) agonists, are insulin sensitizers with reducing risk of CVD, while the potential adverse effects, such as weight gain, fluid retention, bone loss, and cardiovascular risk, restricts its use in diabetic treatment. PPARγ, a ligand-activated nuclear receptor, has shown to play a crucial role in anti-atherosclerosis by promoting cholesterol efflux, repressing monocytes infiltrating into the vascular intima under endothelial layer, their transformation into macrophages, and inhibiting vascular smooth muscle cells proliferation as well as migration. The selective activation of subsets of PPARγ targets, such as through PPARγ post-translational modification, is thought to improve the safety profile of PPARγ agonists. Here, this review focuses on the significance of PPARγ activity regulation (selective activation and post-translational modification) in the occurrence, development and treatment of atherosclerosis, and further clarifies the value of PPARγ as a safe therapeutic target for anti-atherosclerosis especially in diabetic treatment.

Keywords: PPARγ; atherosclerosis; cardiovascular disease; post-translational modifications; selective modulators.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
PPARγ attenuated atherosclerosis through different aspects, including alleviating endothelial dysfunction, promoting cholesterol efflux, inducing M1-M2 transition, inhibiting VSMC migration and proliferation and stabilizing the fibrous cap and plaque.
FIGURE 2
FIGURE 2
Post-translational modification of PPARγ regulates atherosclerosis. (A) Both phosphorylation of PPARγ at S112 by CDK7/9 or MAPK and phosphorylation of PPARγ at S273 accelerates foam cell formation and atherosclerosis through different signaling pathway, some PPARγ agonist (WSF-7, SR1664) can block cdk5 mediated Ser273 phosphorylation. (B) Acetylation of PPARγ at K268/K293 increases atherosclerosis through upregulating ABCA1, ABCG1, and NcoR but inhibiting PRDM16,while deacetylation of PPARγ at K268 and K293 alleviates atherosclerosis, while PPARγ agonist rosiglitazone (Rosi) could deacetylate PPARγ at K268/K293. (C) Sumoylation of PPARγ at K107 promotes VSMCs proliferation and migration, but sumoylation of PPARγ at K395, such as by Rosi, has anti-inflammation effect.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Akiyama T. E., Sakai S., Lambert G., Nicol C. J., Matsusue K., Pimprale S., et al. (2002). Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol. Cell. Biol. 22 2607–2619. 10.1128/MCB.22.8.2607-2619.2002 - DOI - PMC - PubMed
    1. Asteian A., Blayo A. L., He Y., Koenig M., Shin Y., Kuruvilla D. S., et al. (2015). Design, Synthesis, and Biological Evaluation of Indole Biphenylcarboxylic Acids as PPARγ Antagonists. ACS Med. Chem. Lett. 6 998–1003. 10.1021/acsmedchemlett.5b00218 - DOI - PMC - PubMed
    1. Babaev V. R., Yancey P. G., Ryzhov S. V., Kon V., Breyer M. D., Magnuson M. A., et al. (2005). Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 25 1647–1653. 10.1161/01.ATV.0000173413.31789.1a - DOI - PubMed
    1. Banks A. S., McAllister F. E., Camporez J. P., Zushin P. J., Jurczak M. J., Laznik-Bogoslavski D., et al. (2015). An ERK/Cdk5 axis controls the diabetogenic actions of PPARgamma. Nature 517 391–395. 10.1038/nature13887 - DOI - PMC - PubMed
    1. Barros C. D., Amato A. A., de Oliveira T. B., Iannini K. B., Silva A. L., Silva T. G., et al. (2010). Synthesis and anti-inflammatory activity of new arylidene-thiazolidine-2,4-diones as PPARgamma ligands. Bioorg. Med. Chem. 18 3805–3811. 10.1016/j.bmc.2010.04.045 - DOI - PubMed

LinkOut - more resources